November 23, 2021

Myovant Sciences to Participate in the Evercore ISI 4th Annual HealthCONx Conference

November 8, 2021

Nancy Valente, M.D. Joins Myovant Sciences’ Board of Directors

October 26, 2021

Myovant Sciences Announces Financial Results for Second Quarter of Fiscal Year 2021 and Corporate Updates

October 19, 2021

Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress

October 12, 2021

Myovant Sciences to Host Second Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on October 26, 2021

September 9, 2021

Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis

September 1, 2021

Myovant Sciences to Participate in the 2021 Baird Global Healthcare Conference

August 12, 2021

Myovant Sciences Appoints Uneek Mehra as Chief Financial and Business Officer

July 28, 2021

Myovant Sciences Announces Financial Results for First Quarter of Fiscal Year 2021 and Corporate Updates

July 20, 2021

Myovant Sciences Announces European Commission Approval for RYEQO® for the Treatment of Women With Uterine Fibroids